A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Status:
RECRUITING
Trial end date:
2028-08-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). mAPMR is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone treatments designed to block male hormones (androgens).